Glenmark Pharmaceuticals Faces FDA Class II Recall for Rizatriptan Benzoate Due to Nitrosamine Impurity
Glenmark Pharmaceuticals Inc., USA has initiated a Class II recall (D-0535-2024) for 13,296 cartons of Rizatriptan Benzoate Orally Disintegrating Tablets nationwide. This action stems from N-Nitroso Desmethyl Rizatriptan impurity levels exceeding FDA acceptable limits, indicating critical CGMP deviations. Procurement and regulatory teams must assess supply chain stability and quality assurance protocols, particularly for products sourced internationally, given the ongoing regulatory scrutiny on nitrosamine impurities.
Critical FDA Class II Recall: Glenmark's Rizatriptan Benzoate Impacted by Nitrosamine Impurity
Glenmark Pharmaceuticals Inc., USA has initiated a voluntary, firm-initiated Class II recall, designated D-0535-2024, for its Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10mg. This critical action, initiated on May 13, 2024, and reported on June 12, 2024, is a direct response to detected levels of N-Nitroso Desmethyl Rizatriptan impurity that exceed the FDA's acceptable limits, signaling significant Current Good Manufacturing Practice (CGMP) deviations. For procurement directors, this immediately flags a supply risk for a widely used migraine medication under ANDA201914. The presence of nitrosamine impurities, even at trace levels, triggers heightened regulatory scrutiny due to their potential genotoxic and carcinogenic properties. This event underscores the imperative for robust quality control systems throughout the pharmaceutical manufacturing process, particularly for generic drug products where cost pressures can sometimes challenge stringent oversight. Companies sourcing similar molecules or relying on contract manufacturers must immediately review their impurity testing protocols and risk assessments to prevent similar disruptions.
Supply Chain Exposure and Product Specifics: US Nationwide Distribution
The recall encompasses a substantial volume of Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10mg, totaling 13,296 cartons. These products, identified by NDCs such as 68462-468-06, 68462-467-74, and others, were distributed US Nationwide, indicating a broad market exposure for Glenmark Pharmaceuticals Inc., USA, based in Mahwah, NJ. The affected lots include 19223402 (exp. 7/2024), 19224858 (exp. 11/2024), and 19232492 (exp. 6/2025), necessitating a comprehensive retrieval effort across the supply chain. While Glenmark Pharmaceuticals Inc., USA is the recalling firm and manufacturer for the product, the source explicitly states 'Product of India,' highlighting the complexities of global pharmaceutical supply chains. Supply chain VPs must recognize that this geographic origin introduces additional layers of regulatory and quality oversight challenges. The recall's 'Ongoing' status means that the market impact and remediation efforts are still unfolding, requiring continuous monitoring for potential secondary effects on availability and pricing of Rizatriptan Benzoate across the United States.
Mitigating Nitrosamine Risks: Regulatory Scrutiny and CGMP Compliance
The detection of N-Nitroso Desmethyl Rizatriptan impurity falls within a broader industry-wide challenge concerning nitrosamine contamination in pharmaceutical products, a focus area for the FDA since 2018. This event serves as a critical reminder for regulatory affairs heads and business development executives that CGMP deviations related to impurity control are not isolated incidents but reflect systemic vulnerabilities. The Class II classification signifies that the impurity could cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates immediate action from Glenmark to investigate the root cause of the impurity formation, implement robust corrective and preventive actions (CAPA), and demonstrate sustained compliance. Companies must proactively reassess their manufacturing processes, raw material sourcing, and finished product testing strategies to identify and mitigate potential nitrosamine formation pathways. This includes scrutinizing third-party suppliers, particularly for APIs and excipients, and ensuring that their quality management systems meet evolving global regulatory expectations to safeguard patient safety and market access.